PortfoliosLab logo
GH vs. EXAS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GH and EXAS is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

GH vs. EXAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Guardant Health, Inc. (GH) and Exact Sciences Corporation (EXAS). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%60.00%December2025FebruaryMarchAprilMay
29.44%
-26.76%
GH
EXAS

Key characteristics

Sharpe Ratio

GH:

1.79

EXAS:

-0.18

Sortino Ratio

GH:

2.59

EXAS:

-0.00

Omega Ratio

GH:

1.29

EXAS:

1.00

Calmar Ratio

GH:

1.32

EXAS:

-0.22

Martin Ratio

GH:

6.04

EXAS:

-0.68

Ulcer Index

GH:

19.57%

EXAS:

24.05%

Daily Std Dev

GH:

69.66%

EXAS:

59.73%

Max Drawdown

GH:

-91.03%

EXAS:

-98.01%

Current Drawdown

GH:

-76.73%

EXAS:

-65.77%

Fundamentals

Market Cap

GH:

$5.46B

EXAS:

$10.06B

EPS

GH:

-$3.39

EXAS:

-$5.53

PS Ratio

GH:

7.50

EXAS:

3.07

PB Ratio

GH:

55.67

EXAS:

3.46

Total Revenue (TTM)

GH:

$774.00M

EXAS:

$2.83B

Gross Profit (TTM)

GH:

$474.77M

EXAS:

$1.93B

EBITDA (TTM)

GH:

-$397.86M

EXAS:

-$848.74M

Returns By Period

In the year-to-date period, GH achieves a 36.43% return, which is significantly higher than EXAS's -5.57% return.


GH

YTD

36.43%

1M

4.70%

6M

45.79%

1Y

123.61%

5Y*

-13.95%

10Y*

N/A

EXAS

YTD

-5.57%

1M

31.63%

6M

-0.32%

1Y

-10.79%

5Y*

-8.37%

10Y*

8.80%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GH vs. EXAS — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GH
The Risk-Adjusted Performance Rank of GH is 9090
Overall Rank
The Sharpe Ratio Rank of GH is 9494
Sharpe Ratio Rank
The Sortino Ratio Rank of GH is 9292
Sortino Ratio Rank
The Omega Ratio Rank of GH is 8787
Omega Ratio Rank
The Calmar Ratio Rank of GH is 8888
Calmar Ratio Rank
The Martin Ratio Rank of GH is 8989
Martin Ratio Rank

EXAS
The Risk-Adjusted Performance Rank of EXAS is 3838
Overall Rank
The Sharpe Ratio Rank of EXAS is 4242
Sharpe Ratio Rank
The Sortino Ratio Rank of EXAS is 3737
Sortino Ratio Rank
The Omega Ratio Rank of EXAS is 3737
Omega Ratio Rank
The Calmar Ratio Rank of EXAS is 3838
Calmar Ratio Rank
The Martin Ratio Rank of EXAS is 3737
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GH vs. EXAS - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Guardant Health, Inc. (GH) and Exact Sciences Corporation (EXAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current GH Sharpe Ratio is 1.79, which is higher than the EXAS Sharpe Ratio of -0.18. The chart below compares the historical Sharpe Ratios of GH and EXAS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
1.79
-0.18
GH
EXAS

Dividends

GH vs. EXAS - Dividend Comparison

Neither GH nor EXAS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

GH vs. EXAS - Drawdown Comparison

The maximum GH drawdown since its inception was -91.03%, smaller than the maximum EXAS drawdown of -98.01%. Use the drawdown chart below to compare losses from any high point for GH and EXAS. For additional features, visit the drawdowns tool.


-85.00%-80.00%-75.00%-70.00%-65.00%-60.00%December2025FebruaryMarchAprilMay
-76.73%
-65.77%
GH
EXAS

Volatility

GH vs. EXAS - Volatility Comparison

Guardant Health, Inc. (GH) has a higher volatility of 21.27% compared to Exact Sciences Corporation (EXAS) at 17.33%. This indicates that GH's price experiences larger fluctuations and is considered to be riskier than EXAS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%December2025FebruaryMarchAprilMay
21.27%
17.33%
GH
EXAS

Financials

GH vs. EXAS - Financials Comparison

This section allows you to compare key financial metrics between Guardant Health, Inc. and Exact Sciences Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


100.00M200.00M300.00M400.00M500.00M600.00M700.00M20212022202320242025
203.47M
706.79M
(GH) Total Revenue
(EXAS) Total Revenue
Values in USD except per share items

GH vs. EXAS - Profitability Comparison

The chart below illustrates the profitability comparison between Guardant Health, Inc. and Exact Sciences Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%65.0%70.0%75.0%80.0%20212022202320242025
63.3%
70.8%
(GH) Gross Margin
(EXAS) Gross Margin
GH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Guardant Health, Inc. reported a gross profit of 128.75M and revenue of 203.47M. Therefore, the gross margin over that period was 63.3%.

EXAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Exact Sciences Corporation reported a gross profit of 500.55M and revenue of 706.79M. Therefore, the gross margin over that period was 70.8%.

GH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Guardant Health, Inc. reported an operating income of -111.04M and revenue of 203.47M, resulting in an operating margin of -54.6%.

EXAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Exact Sciences Corporation reported an operating income of -96.01M and revenue of 706.79M, resulting in an operating margin of -13.6%.

GH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Guardant Health, Inc. reported a net income of -95.16M and revenue of 203.47M, resulting in a net margin of -46.8%.

EXAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Exact Sciences Corporation reported a net income of -101.22M and revenue of 706.79M, resulting in a net margin of -14.3%.